TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: parent satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of high-level (99233) notes generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day-28 cumulative PCR-corrected efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of chest compressions in target depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the release phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urea removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hr PM2.5 exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: functional levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diagnostic accuracy of the algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants reaching HbA1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access site–related bleeding (type 3 or 5)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of vital bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in unassisted swing length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-monitoring and goal setting
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: App acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADHD symptoms measured by ASRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior mean gamma power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Posterior relative alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peak systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge of MBD as a masking and risk factor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants speaking with a provider about MBD
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: IL-6 levels at 1 month postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of recurrence associated with IL-6 levels
Endpoint domain: Mortality/survival
Primary endpoint: total inflammatory cells per mm2 thrombus area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neutrophils per mm2 thrombus area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: myeloperoxidase-positive cells per mm2 thrombus area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: internal mammary artery graft occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative urinary retention rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AST and ALP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PI and GI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total performance error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak amplitude error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes of skin-to-skin care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved daily work routine
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decreased work motivation strain symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wound healing by secondary intention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: %FMD improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QT/QTcF ≥500 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ≥60 ms QTcF increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NRS pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage decrease in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement in time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean improvement in path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment retention time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of illness score (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of those without periodontal diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of active caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community periodontal index (CPI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of self-reported weight category
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total score (T‐score) of ASRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in active sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of time in quiet sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proliferation ability of CPCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days of apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproductive-health-promoting behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decrease in MACBAR of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year patient-reported and functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Age-appropriately immunised infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of employees reporting having a primary care physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employee health beliefs about health risks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of isolates with plasmid mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in outcomes in HZO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in anatomic knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: learner engagement and motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hormonal measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of E.f
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hemoglobin (Hb) changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with an Hb response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percent reductions in inflammatory and noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AF detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inappropriate therapy reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Slowed slope of eGFR decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Engagement with the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 5-year overall survival benefit
Endpoint domain: Mortality/survival
Primary endpoint: Cohen‐Mansfield Agitation Inventory score reduction of ≥ 4 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cohen‐Mansfield Agitation Inventory score reduction of ≥ 8 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of dnDSA
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of the end product (anatomy exposed and lymphadenectomy performed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: recovery of upper extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted mean maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to reach Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean self-help change score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stimulated monocyte production of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Co-expression of IL-6 with TNF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Culture positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidences of mild to moderate BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biventricular systolic and diastolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of prostate cancer
Endpoint domain: Adverse events/effects
Primary endpoint: average blood glucose readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Student satisfaction with VR technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean score of students in learning process
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: daily pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clonus scale remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAC remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean between-group difference in IIEF-EF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of phenolic compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ApoB‐48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EBF duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBF rates at 6th month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic gallstone disease
Endpoint domain: Adverse events/effects
Primary endpoint: cholecystectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Traditional Chinese Medicine symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deficits in exocentric movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary diversity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthcare visits for illnesses
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Yoga performance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-FXa activity Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-FIIa activity Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of endoscopic tattoo
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative visibility of the endoscopic tattoo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPS response reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective unpleasantness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access opening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultimate load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First failure load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half maximal effective concentration (EC50) in human whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pharmacokinetics outcomes
Primary endpoint: Surgical wound length of stay (SWLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HHS (Hip Harris Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positional stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time spent on a case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Apnea-Hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mental health and well-being assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean L5 decrease from baseline to week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS mean change from baseline to week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percentage change from baseline to week 4 in MDSB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood swings
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with planned drug administration
Endpoint domain: Resource use
Primary endpoint: Self-perceived resonant voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in phonatory effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: Disulfide values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative native thiol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NfL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ARI-related hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number needed to treat to prevent hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants completing the trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete wound healing at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of IL-17A with PDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of peak pressures in the heel, forefoot and 5th metatarsophalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure time integrals in the heel, forefoot and 5th metatarsophalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased midfoot contact with the trial device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood culture-confirmed typhoid fever incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dialysis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scalp sebum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of depression (HAMD17 and SDS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of anxiety (HAMA and SAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of insomnia (AIS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech difficulties reported by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oswestry Disability Questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in genital psoriasis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average elevation in total creatine content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Night-time pad use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional impairment in adolescents with ADHD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in trimethylamine‐N‐oxide (TMAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in alanine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in β‐hydroxybutyrate (BHB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain severity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intraoperative Blood Loss (IBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total surgical time
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Motor and sensory function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average Rate of Progression (RoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifetime reports of PTEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tensile strength when the first transmural rupture appeared (MATS‐2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal strength (MATS‐3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necrosis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histologically confirmed lesion clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 viral load > 1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of being underweight (BMI < 18.5 kg/m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain intensity (SPID6rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Neuropsychological T-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACT-COG-PCI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: FIA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anti-KLH IgM titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-KLH IgG titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skin blood perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety voice usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety participation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ergonomic practices adoption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Seroprotection by HAI three weeks after H7N9 IIV dose 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes